Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50...

68
Oncology Oncology Human Population Human Population about 6 000 000 000 about 6 000 000 000 Women Population Women Population about 3 500 000 000 about 3 500 000 000 Women > 50 years Women > 50 years about 1 000 000 000 about 1 000 000 000 ENDOMETRIAL CARCINOMA ENDOMETRIAL CARCINOMA 150 000 150 000 new cases annually new cases annually

Transcript of Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50...

Page 1: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

OncologyOncology

Human PopulationHuman Population about 6 000 000 000about 6 000 000 000

Women Population Women Population about 3 500 000 000about 3 500 000 000

Women > 50 yearsWomen > 50 years about 1 000 000 000about 1 000 000 000

ENDOMETRIAL CARCINOMAENDOMETRIAL CARCINOMA

150 000150 000 new cases annuallynew cases annually

Page 2: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Uterine Corpus TumorsUterine Corpus Tumors

• ENDOMETRIUMENDOMETRIUM

• MYOMETRIUMMYOMETRIUM

Endometrial stroma

Endometrial polyps

Endometrial glands

Endometrial carcinoma

Mixed Mesodermal

Tumors

Stromal Nodule

Stromal Sarcoma

LEIOMYOMA

LEIOMYOSARCOMA

Page 3: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Endometrial CarcinomaEndometrial Carcinoma

Second mSecond most common genital tract ost common genital tract malignancymalignancy

(after cervical carcinoma)(after cervical carcinoma)150 000 annually all over the world150 000 annually all over the world

35 000 annually in USA35 000 annually in USANumber of cases still risingNumber of cases still rising

Page 4: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Endometrial CarcinomaEndometrial Carcinoma

The best example of en estrogen-depended The best example of en estrogen-depended neoplasmneoplasm

Risk factors associated with the Risk factors associated with the estrogen-rich environmentestrogen-rich environment

With early diagnosis survival rate With early diagnosis survival rate can be excellentcan be excellent

Page 5: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

EpidemiologyEpidemiologyIncidencesIncidences

USA (white women)USA (white women)Swiss, Denmark, GermanySwiss, Denmark, Germany

France, Sweden France, Sweden NorwayNorway

POLANDPOLAND

India, Japan, Kuwait, FilipinaIndia, Japan, Kuwait, Filipina

Page 6: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

EpidemiologyEpidemiology

POLANDPOLAND

morbiditymorbidity - V - V placeplace (11,8%) (11,8%)

mortalitymortality- XIV - XIV placeplace (2,5%) (2,5%)

Page 7: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

EpidemiologyEpidemiology

55-90 r.ż. 55-90 r.ż. Almost all cases in postmenopausal ageAlmost all cases in postmenopausal age

(two pick(two picks s of morbidity: about 55 y. and 78 of morbidity: about 55 y. and 78 y.)y.)

5% < 40 r.ż.5% < 40 r.ż.

Page 8: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

PathogenesisPathogenesis

• Estrogen dependent carcinomaEstrogen dependent carcinoma ((progressing of changes about 10 yearsprogressing of changes about 10 years))

endometrialendometrial typicaltypical atypicalatypical

proliferationproliferation hyperplasiahyperplasia hyperplasia hyperplasia CarcinomaCarcinoma

• Estrogen independent carcinomaEstrogen independent carcinoma

normalnormal CarcinomaCarcinoma

endometriumendometrium

Page 9: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Sexual Hormones Sexual Hormones ActivityActivity

ESTROGENSESTROGENSstimulating divistimulating divissiionon of cells of cells

PROGESTAGESPROGESTAGESbreaking divibreaking divisonson of cells of cells

Page 10: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Sexual Hormones productionSexual Hormones production Reproductive ageReproductive age

EE11, ,

EE22, E, E33

OVARIESOVARIES ProgesteroneProgesterone

TestosteroneTestosterone

AndrostendioneAndrostendione

ADRENAL GLANDS AndrostendioneADRENAL GLANDS Androstendione

Page 11: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Sexual Hormones productionSexual Hormones production Premenopausal periodPremenopausal period

EE11, ,

EE22, E, E33

OVARIESOVARIES ProgesteroneProgesterone

TestosteroneTestosterone

AndrostendioneAndrostendione

ADRENAL GLANDS AndrostendioneADRENAL GLANDS Androstendione

Reletive Reletive HyperestrogenismsHyperestrogenisms

Page 12: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Sexual Hormones productionSexual Hormones production Postmenopausal PeriodPostmenopausal Period

OVARIESOVARIES TestosteroneTestosterone

ADRENAL GLANDS ADRENAL GLANDS AndrostendioneAndrostendione

Androgens aromatization into estrogensAndrogens aromatization into estrogensAndrostendioneAndrostendione EstronEstronTestosteroneTestosterone EstradiolEstradiol

Page 13: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

PathogenesisPathogenesishormonal factorshormonal factors

• ESTRONESTRONEE

• ESTRADIOLESTRADIOL

• ANDROGENSANDROGENS

• ESTRIOLESTRIOL

• PROGESTERONEPROGESTERONE

Page 14: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

RISK FACTORSRISK FACTORS

ObesityObesity Late menopause > 52 years-old womenLate menopause > 52 years-old women NulliparityNulliparity Anovulatory cyclesAnovulatory cycles PCOsPCOs Ovarian tumors (hormonal active)Ovarian tumors (hormonal active) Diabetes mellitus type IIDiabetes mellitus type II Hepatic cirrhosis Hepatic cirrhosis Hypothyroidism Hypothyroidism HyperprolactinemiaHyperprolactinemia

Page 15: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Protective FactorsProtective Factors

Oral contraceptionOral contraception

Complex hormonal replacement therapyComplex hormonal replacement therapy

Cigarettes smoking Cigarettes smoking

Page 16: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

EndometrialEndometrial CarcinomaCarcinoma

Symptoms Symptoms

• Postmenopausal bleedingPostmenopausal bleeding

• Acyclic bleeding in premenopausal Acyclic bleeding in premenopausal

periodperiod

• ill – smelling leucorreasill – smelling leucorreas

• pelvic painpelvic pain

• ascitesascites

Page 17: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Postmenopausal bleedingPostmenopausal bleedingmain reasonsmain reasonsPostmenopausal bleedingPostmenopausal bleedingmain reasonsmain reasons

Endometrial atrophyEndometrial atrophy 50 %50 %

Endometrial polypEndometrial polyp 15 %15 %

Submucosus uterine myomaSubmucosus uterine myoma 10 %10 %

Endometrial hyperplasiaEndometrial hyperplasia 10 %10 %

Endometrial carcinomaEndometrial carcinoma 5 % 5 %

Cervix disease (CA, polypsCervix disease (CA, polyps)) 10 %10 %

Page 18: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

AAsymptomatic casessymptomatic casesUltrasonography Ultrasonography

Estimated FeaturesEstimated Features

thicknessthickness echogenicity et structure echogenicity et structure middle echo middle echo fluid in uterine cavityfluid in uterine cavity endo-myometral borderendo-myometral border

focal lesionsfocal lesions

Page 19: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Normal ultrasonographic image of Normal ultrasonographic image of endometrium of postmenopausal womenendometrium of postmenopausal women

Page 20: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Abnormal ultrasonographic image of Abnormal ultrasonographic image of endometrium of postmenopausal womenendometrium of postmenopausal women

Page 21: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Precancerous LesionsPrecancerous Lesions

Simple endometrial hyperplasia Simple endometrial hyperplasia without atypia without atypia Complex hyperplasia without atypia Complex hyperplasia without atypia

Endometrial polypsEndometrial polyps

Atypical endometrial hyperplasiaAtypical endometrial hyperplasia ( simple or complex)( simple or complex)

Page 22: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

EndometrialEndometrial CarcinomaCarcinoma

DiagnosisDiagnosis

On baseOn base

morphological research morphological research

The material The material

received from uterine cavity received from uterine cavity

Page 23: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Methods of Receiving of Methods of Receiving of Material from Uterine CavityMaterial from Uterine Cavity

Endometrial Cytology Endometrial Cytology (Gynoscan, Endo-Pap, Jet-Wash)(Gynoscan, Endo-Pap, Jet-Wash)

Endometrial Biopsy Endometrial Biopsy

(Pipella, Vabra)(Pipella, Vabra) D & C D & C Diagnostic HysteroscopyDiagnostic Hysteroscopy

Page 24: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Dilatation and CurettageDilatation and Curettage

Recamier 1843Recamier 1843

Most often diagnostic interventionMost often diagnostic intervention

executed in worldexecuted in world

„„gold standard”gold standard”

Page 25: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Dilatation and CurettageDilatation and Curettage

blind procedureblind procedure general anaesthesiageneral anaesthesia high grade of uterine perforation 1/99 high grade of uterine perforation 1/99 risk of haemorrhagerisk of haemorrhage risk of infectionrisk of infection most often only 50 % of most often only 50 % of

endometrial surface is receivedendometrial surface is received

Page 26: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Diagnostic HysteroscopyDiagnostic Hysteroscopy

estimation under eye-controlestimation under eye-control all endometrial surface is accessible to all endometrial surface is accessible to

investigationinvestigation target biopsytarget biopsy local anaesthesialocal anaesthesia video documentationvideo documentation

low grade of uterine perforations low grade of uterine perforations

Page 27: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

abnormal USG image of endometriumabnormal USG image of endometrium

at asymptomatic womanat asymptomatic woman

focal changes in USG image of focal changes in USG image of

endometrium endometrium

abnormal USG + D&C /-/abnormal USG + D&C /-/

recurrent uterine bleeding + D&C /-/recurrent uterine bleeding + D&C /-/

unsuccessful D&Cunsuccessful D&C

Diagnostic Hysteroscopy – WHEN ?Diagnostic Hysteroscopy – WHEN ?

Page 28: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.
Page 29: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.
Page 30: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.
Page 31: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.
Page 32: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.
Page 33: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.
Page 34: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.
Page 35: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

FIGO Surgical Staging of Endometrial FIGO Surgical Staging of Endometrial CarcinomaCarcinoma

I A Tumor limited to endometriumI A Tumor limited to endometriumI B Invasion to less then one half of the I B Invasion to less then one half of the

myometrium myometriumI C Invasion to more then one half of myometriumI C Invasion to more then one half of myometriumII A Endocervical glandular involvementII A Endocervical glandular involvementII B Cervical stromal involvementII B Cervical stromal involvementIII A Tumor involving serosa and/or adnexa or III A Tumor involving serosa and/or adnexa or

positive peritoneal cytology positive peritoneal cytologyIII B Vaginal metastasesIII B Vaginal metastasesIII C Metastases to pelvic and/or periaortic lymph III C Metastases to pelvic and/or periaortic lymph

nodes nodes IV A Tumor invades bladder mucosa or bowel IV A Tumor invades bladder mucosa or bowel IV B Distant metastases IV B Distant metastases

Page 36: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

FIGO Surgical Staging of Endometrial CarcinomaFIGO Surgical Staging of Endometrial Carcinoma

First StageFirst StageTumor Limited to Uterine CorpusTumor Limited to Uterine Corpus

I AI A Tumor limited to endometrium Tumor limited to endometriumI BI B Invasion to less then one half of Invasion to less then one half of

myometrium myometrium

I CI C Invasion to more then one half of Invasion to more then one half of myometrium myometrium

Page 37: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

FIGO Surgical Staging of Endometrial CarcinomaFIGO Surgical Staging of Endometrial Carcinoma

Second StageSecond Stage

Tumor Invading Uterine CervixTumor Invading Uterine Cervix

II AII A Endocervical glandular involvement Endocervical glandular involvement

II BII B Cervical stromal involvementCervical stromal involvement

Page 38: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Histological Grading Histological Grading of Endometrial Carcinomaof Endometrial Carcinoma

• G 1G 1 Less then 5 % Less then 5 %

undifferentiated cells undifferentiated cells

• G 2G 2 5 – 50 % undifferentiated cells5 – 50 % undifferentiated cells

• G 3G 3 More then 50 % More then 50 %

undifferentiated cellsundifferentiated cells

• G XG XNumber of undifferentiated cells Number of undifferentiated cells

is unknown is unknown

Page 39: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

FIGO Surgical Staging of Endometrial CarcinomaFIGO Surgical Staging of Endometrial Carcinoma

Third StageThird Stage

Tumor Out of UterusTumor Out of Uterus

III AIII A Tumor involving serosa and/or adnexa Tumor involving serosa and/or adnexa

or positive peritoneal cytologyor positive peritoneal cytology

III BIII B Vaginal metastasesVaginal metastases

III CIII C Metastases to pelvic and/or Metastases to pelvic and/or

periaortic lymph nodes periaortic lymph nodes

Page 40: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

FIGO Surgical Staging of Endometrial CarcinomaFIGO Surgical Staging of Endometrial Carcinoma

Forth StageForth Stage

IV AIV A Tumor invades bladder mucosa or bowel Tumor invades bladder mucosa or bowel

IV BIV B Distant metastasesDistant metastases

Page 41: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Endometrial CarcinomaEndometrial Carcinoma hystological types, WHO classification hystological types, WHO classification

Adenocarcinoma - endometrioide typeAdenocarcinoma - endometrioide type

Mucinous Mucinous aadenocarcinomadenocarcinoma

Serous Serous aadenocarcinoma denocarcinoma

Clear cell Clear cell aadenocarcinomadenocarcinoma

Carcinoma planoepithelialeCarcinoma planoepitheliale

Carcinoma mixtumCarcinoma mixtum

Undifferented Undifferented ccarcinomaarcinoma

Page 42: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Treatment of EndometrialTreatment of Endometrial CarcinomaCarcinoma

• SurgerySurgery

• Radiotherapy Radiotherapy

• HormonotherapyHormonotherapy

• ChemotherapyChemotherapy

Page 43: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Treatment of EndometrialTreatment of Endometrial CarcinomaCarcinoma

SURGERYSURGERYdependent of stagedependent of stage

• TAH with bilateral oophorectomyTAH with bilateral oophorectomy

• TAH with bilateral oophorectomy TAH with bilateral oophorectomy

and 1/3 part of vaginaand 1/3 part of vagina

• Radical HysterectomyRadical Hysterectomy

• Tumorectomy (debulking operation)Tumorectomy (debulking operation)

Page 44: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Treatment of EndometrialTreatment of Endometrial CarcinomaCarcinoma

RadioRadiotherapytherapydependent of stagedependent of stage

• Neo-adjuvant brachytherapyNeo-adjuvant brachytherapy

• Adjuvant brachytherapy Adjuvant brachytherapy

Radium, Cobalt, Cesium, IridiumRadium, Cobalt, Cesium, Iridium

• TeletherapyTeletherapy

X-ray, gamma-ray, electron-rayX-ray, gamma-ray, electron-ray

Page 45: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Treatment of EndometrialTreatment of Endometrial CarcinomaCarcinoma

HormonotherapyHormonotherapydependent of receptors statusdependent of receptors status

• Gestagens – high dosesGestagens – high doses

medroxyprogesterone, megestrol etcmedroxyprogesterone, megestrol etc

• inhibitor of aromatase inhibitor of aromatase aminoglutetymidaminoglutetymid

Page 46: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Treatment of EndometrialTreatment of Endometrial CarcinomaCarcinoma

Chemotherapy Chemotherapy last chance therapylast chance therapy

• Mono - chemotherapyMono - chemotherapy

CCis-platinum, Carboplatinum, Taxolis-platinum, Carboplatinum, Taxol

• Poly - chemotherapy Poly - chemotherapy Cis-platinum, cyclophosphamidum, Malfelan, Cis-platinum, cyclophosphamidum, Malfelan,

5-fluorouracyl, Doxorubicin5-fluorouracyl, Doxorubicin

PAC, CAP, FAC, ACPAC, CAP, FAC, AC

Page 47: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Treatment of EndometrialTreatment of Endometrial CarcinomaCarcinoma

Stage I a Grade 1Stage I a Grade 1

• TAH with bilateral oophorectomyTAH with bilateral oophorectomy

• BrachytherapyBrachytherapy

(when surgery is contraindicated)(when surgery is contraindicated)

Page 48: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Treatment of EndometrialTreatment of Endometrial CarcinomaCarcinoma

Stage I a Grade 2, 3Stage I a Grade 2, 3

• TAH with bilateral oophorectomy TAH with bilateral oophorectomy

andand

• BrachytherapyBrachytherapy

Page 49: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Treatment of EndometrialTreatment of Endometrial CarcinomaCarcinoma

Stage I b, c, Stage II Stage I b, c, Stage II Stage III a Stage III a

• TAH + BO or Radical Hysterectomy TAH + BO or Radical Hysterectomy

• BrachytherapyBrachytherapy

• TeletherapyTeletherapy

• Hormonotherapy ( EHormonotherapy ( E22R +, PgR + orR +, PgR + or EE22R -, PgR + )R -, PgR + )

Page 50: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Treatment of EndometrialTreatment of Endometrial CarcinomaCarcinoma

Stage III b, c Stage IV Stage III b, c Stage IV

• Tumorecromy Tumorecromy

• Hormonotherapy ( EHormonotherapy ( E22R +, PgR + orR +, PgR + or

EE22R -, PgR + )R -, PgR + )

• ChemotherapyChemotherapy

Page 51: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

EndometrialEndometrial CarcinomaCarcinoma

Prognostic Factors Prognostic Factors

• AgeAge• StageStage• GradeGrade• Presence of myometrial invasionPresence of myometrial invasion• Presence of NEO cells in peritoneal fluidPresence of NEO cells in peritoneal fluid• Lymph node metastasesLymph node metastases• Receptor statusReceptor status• DNA content in neoplastic cellsDNA content in neoplastic cells

Page 52: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Prognosis in Endometrial CarcinomaPrognosis in Endometrial Carcinoma

5 YEAR SURVIVAL 5 YEAR SURVIVAL

• Stage IStage I 75 – 100 %75 – 100 %

• Stage IIStage II 50 – 65 %50 – 65 %

• Stage IIIStage III 20 – 40 % 20 – 40 %

• Stage IVStage IV below 10 %below 10 %

Page 53: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.
Page 54: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

5 YEAR SURVIVAL 5 YEAR SURVIVAL

• Endometrial CarcinomaEndometrial Carcinoma 75 %75 %

• Vulnar CarcinomaVulnar Carcinoma 42 %42 %

• Cervical CarcinomaCervical Carcinoma 38 %38 %

• Ovarian carcinomaOvarian carcinoma 35 %35 %

Page 55: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.
Page 56: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.
Page 57: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Diagnostic of asymptomatic womenDiagnostic of asymptomatic women

TV - USGTV - USG

No changesNo changes Indistinct Image Indistinct Image abnormal imageabnormal image

Control TV – USGControl TV – USG

After 3 monthsAfter 3 monthsSonohysterographySonohysterography HysteroscopyHysteroscopy

No changesNo changes abnormal imageabnormal image

Control TV – USGControl TV – USG

After 3 monthsAfter 3 months HysteroscopyHysteroscopy

Histological Histological

DiagnosisDiagnosis

HistologicalHistological

DiagnosisDiagnosis

Page 58: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

INDIRECT METHODINDIRECT METHODOF ENDOMETRAL ASSESSMENTOF ENDOMETRAL ASSESSMENT

Conventional USGConventional USG Transvaginal USGTransvaginal USG Doppler MethodDoppler Method SonohysterogrphySonohysterogrphy 3D-ultrasonography3D-ultrasonography Magnetic ResonanceMagnetic Resonance Computer TomographyComputer Tomography

Page 59: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Conventional UltrasonographyConventional Ultrasonography(problems)(problems)

ObesityObesity

Fill up bladder problems Fill up bladder problems

(urinary incontinence)(urinary incontinence)

retroflexion of uterine corpusretroflexion of uterine corpus

low frequency 3,5-5 MHzlow frequency 3,5-5 MHz

Page 60: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Transvaginal UltrasonographyTransvaginal Ultrasonography

USG head near the uterus USG head near the uterus

Empty bladder Empty bladder

High frequency 6-15 MHzHigh frequency 6-15 MHz

Low rangeLow range

Page 61: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

USGUSG Doppler MethodDoppler Method

neoangiogenesisneoangiogenesis

uterine artery flowuterine artery flow

small endometrial arteries flow small endometrial arteries flow

RIRI PIPI

Page 62: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

HYSTEROSONOGRAPHYHYSTEROSONOGRAPHY3D - hysterography3D - hysterography

5-10 ml 0,9 NaCl, Ringer, H5-10 ml 0,9 NaCl, Ringer, H22OO

when unclear TV-USG image when unclear TV-USG image

special to detect focal lesion special to detect focal lesion

PREPOST

T. C. Dubinsky - J Ultrasound Med 1997

Page 63: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Computer TomofraphyComputer TomofraphyMagnetic ResonanceMagnetic Resonance

comparable with TV-USG in comparable with TV-USG in

assessment of endometrium assessment of endometrium

better in invasion assessment better in invasion assessment

of myometrium by endometrial CA of myometrium by endometrial CA

rather expensiverather expensive

PREPOST

Page 64: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

PREPOST

• Kratochwill 1969

• Fleischer 1984

Diagnostic method which most Diagnostic method which most contributed to development of contributed to development of gynaecology in the course last gynaecology in the course last decades is certainly decades is certainly transvaginal ultrasonographytransvaginal ultrasonography

Diagnostic method which most Diagnostic method which most contributed to development of contributed to development of gynaecology in the course last gynaecology in the course last decades is certainly decades is certainly transvaginal ultrasonographytransvaginal ultrasonography

Page 65: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

USG image of endometriumUSG image of endometriumin postmenopausal periodin postmenopausal period

„„Pencil line”Pencil line”

FLAICHERFLAICHER 6,0 mm6,0 mm

GOLDSTEINGOLDSTEIN 5,0 mm5,0 mm

GRANBERG GRANBERG 5,0 mm5,0 mm

NASSRINASSRI 5,0 mm5,0 mm

OSMERSOSMERS 4,0 mm 4,0 mm

WIKLANDWIKLAND 4,0 mm4,0 mm

Page 66: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Operative HysteroscopyOperative Hysteroscopy indications et postmenopausal womenindications et postmenopausal women

removing of endometrial polypsremoving of endometrial polyps

removing of submucosus myomasremoving of submucosus myomas

( type 0 and I)( type 0 and I)

electroresection of endometriumelectroresection of endometrium

Page 67: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Endometrial hyperplasiaEndometrial hyperplasia treatmenttreatment

• Stimulating ovulation MDsStimulating ovulation MDs • Gestagens – High doseGestagens – High dose• IUD with gestagensIUD with gestagens• hysteroscopic endometrial resectionhysteroscopic endometrial resection• brahy - therapy brahy - therapy • hysterectomyhysterectomy

Page 68: Oncology Human Populationabout 6 000 000 000 Women Population about 3 500 000 000 Women > 50 yearsabout 1 000 000 000 ENDOMETRIAL CARCINOMA 150 000 new.

Endometrial hyperplasiaEndometrial hyperplasiaimportance of using gestagensimportance of using gestagens

• blocking of E-receptors synthesisblocking of E-receptors synthesis

• blocking of gonadotropinblocking of gonadotropin

• increase activity of 5increase activity of 5αα-reductase-reductase

• increase activity Eincrease activity E22-dehydrogenase-dehydrogenase